AbCellera Reports Q2 2026 Business Results
AbCellera (Nasdaq: ABCL) reported Q2 2026 results. Net loss was $55.4 million versus $34.7 million in Q2 2025, with revenue of $4.1 million versus $17.1 million. R&D was $46.0 million and SG&A $13.9 million. The company said Phase 2 ABCL635 top-line data is expected in August 2026 and reported $565 million in cash and marketable securities.
How this was made
The 30-second read
Why it matters
Q2 2026 adds multiple new collaboration announcements and liquidity detail, while financial performance deteriorated versus the prior year quarter. The next major fundamental inflection highlighted is Phase 2 top-line data for ABCL635 expected in August 2026.
Market read
Traders can reassess near-term catalyst timing (ABCL635 Phase 2 readout) and deal-driven liquidity (upfront payments) against weaker reported revenue and higher net loss.
What to watch
Partner program count fell (35 vs 44 at Dec 31, 2025), which could indicate portfolio churn or reduced downstream stakes even as new collaborations add cash.
Background
AbCellera is a clinical-stage biotech focused on antibody-based medicines and T-cell engager platform collaborations.
Ticker impact
AbCellera reported Q2 2026 results and disclosed $84M upfront from new Jazz collaboration plus $28M upfront from a Vertex collaboration.
Near-term bias upward on the collaboration cash and pipeline momentum, partially offset by weaker revenue and higher net loss.
Fresh upfront payments and additional clinical/pipeline catalysts can support sentiment, but the financials show declining revenue and larger net loss, which can cap upside until trial readouts land.
Market effects
Reinforces investor appetite for platform-based biotech deals tied to T-cell engager programs, with emphasis on upfront cash and milestone optionality.
Limited direct regional spillover; primarily impacts US-listed biotech sentiment.
Moderate, as collaborations with large pharma (Jazz, Vertex) signal continued global outsourcing and partnering in immuno-oncology/autoimmune.
Counterpoint
Upfront payments may not translate into near-term revenue, and the quarter’s revenue decline plus larger net loss suggests burn-rate pressure until clinical milestones de-risk value.
Key entities
- companyAbCellera Biologics Inc.
Nasdaq-listed clinical-stage biotech reporting Q2 2026 results and new T-cell engager collaborations.
- companyJazz Pharmaceuticals plc
Partnered with AbCellera on next-generation T-cell engagers for gastrointestinal cancers and other solid tumors.
- companyVertex Pharmaceuticals Incorporated
Partnered with AbCellera on multispecific T-cell engagers for autoimmune diseases and other conditions.
- programABCL635
Phase 2 study with top-line data readout expected in August 2026.
